The FDA recently approved Guardant Health’s “Shield” blood test for colorectal cancer (CRC) screening in adults aged 45 and older who are at average risk for the disease. It is the first blood test to ...
to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer. Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal cancer tumor DNA to aid ...
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund. The US Preventive Services Task Force ...
(DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert test. The stool-based test, utilizing polymerase chain reaction technology, detects colorectal ...
New Study Shows at-Home Colon Cancer Screening Test Reduces Risk of Colorectal Cancer Death, as Effective as Screening Colonoscopy July 25, 2024 — A noninvasive colorectal cancer screening test ...